3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Neoplasm Metastasis
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
17
Nivolumab
6
Docetaxel
6
Gemcitabine
5
Cisplatin
5
Carboplatin
5
durvalumab
4
Paclitaxel
4
Ipilimumab
4
avelumab
3
atezolizumab
3
Filgrastim
3
Cyclophosphamide
3
Bortezomib
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
tislelizumab
2
spartalizumab
2
fludarabine
2
epacadostat
2
enzalutamide
2
aldesleukin
2
abiraterone
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Nicotine
2
Irinotecan
2
Interleukin-2
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
futibatinib
×
Head & Neck
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled